Clinical focus DiaMedica is a clinical-stage biopharma focusing on preeclampsia and acute ischemic stroke, signaling opportunities to align with specialists in obstetrics, neurology, stroke centers, and maternal-fetal medicine for potential collaborative trials, advisory roles, and strategic partnerships.

Strategic leadership Recent leadership changes include appointment of a new Chief Medical Officer and board updates, signaling a potential window for executive outreach to explore clinical collaboration, trial design input, and sponsor opportunities for DM199 related programs.

Investment activity Funding and revenue bands suggest a growing biotech with a substantial funding runway; engage with near-term investors and strategic partners at investor conferences to discuss partnering on late-stage development, licensing, or co-development opportunities.

Key programs DM199 (rinvecalinase alfa) in preeclampsia is a core program; sales outreach should target obstetrics, maternal-fetal medicine, and high-risk pregnancy centers for potential trials, compassionate use discussions, and eventual commercialization partnerships.

Outreach channels Active participation in capital markets conferences and investor events (RBC, Oppenheimer, etc.) indicates a need to coordinate multi-channel outreach to executives, KOLs, and potential clinical partners through tailored presentations and executive briefings.